Subramanian, Advait http://orcid.org/0000-0003-0557-9771
Wang, Lan http://orcid.org/0000-0002-8931-7201
Moss, Tom
Voorhies, Mark
Sangwan, Smriti
Stevenson, Erica
Pulido, Ernst H.
Kwok, Samentha
Chalkley, Robert J. http://orcid.org/0000-0002-9757-7302
Li, Kathy H.
Krogan, Nevan J. http://orcid.org/0000-0003-4902-337X
Swaney, Danielle L.
Burlingame, Alma L. http://orcid.org/0000-0002-8403-7307
Floor, Stephen N. http://orcid.org/0000-0002-9965-9694
Sil, Anita
Walter, Peter http://orcid.org/0000-0002-6849-708X
Mukherjee, Shaeri http://orcid.org/0000-0003-3820-0174
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01GM140440, R01GM144378, 1K99GM143527-01A1, U19 AI135990, DP2GM132932, R01AI136735, R01GM032384)
Damon Runyon Cancer Research Foundation
Howard Hughes Medical Institute
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Article History
Received: 8 November 2022
Accepted: 1 September 2023
First Online: 19 October 2023
Competing interests
: P.W. is an inventor on US Patent 9708247 held by the Regents of the University of California that describes ISRIB and its analogues. Rights to the invention have been licensed by UCSF to Calico. The N.J.K. laboratory has received research support from Vir Biotechnology, F. Hoffmann-La Roche and Rezo Therapeutics. N.J.K. has financially compensated consulting agreements with the Icahn School of Medicine at Mount Sinai, New York, Maze Therapeutics, Interline Therapeutics, Rezo Therapeutics, GEn1E Lifesciences, Inc, and Twist Bioscience Corp. N.J.K. is on the Board of Directors of Rezo Therapeutics and is a shareholder in Tenaya Therapeutics, Maze Therapeutics, Rezo Therapeutics and Interline Therapeutics. D.L.S. has a consulting agreement with Maze Therapeutics and Rezo Therapeutics. All other authors declare no competing interests.